Yposkesi, An Sk Pharmteco Company

Yposkesi, An Sk Pharmteco Company company information, Employees & Contact Information

***This page has moved and is no longer active. Please follow us @SK pharmteco for all company news and updates.*** Yposkesi, an SK pharmteco company, is one of Europe’s largest Contract Development and Manufacturing Organizations (CDMO) for gene therapy viral vector manufacturing. As a trusted partner for biotech and pharmaceutical companies seeking to advance clinical trials and commercialize new Advanced Therapy Medicinal Products (ATMPs), Yposkesi offers a full range of services in lentiviral vectors and AAV (Adeno-Associated Virus) cGMP manufacturing. Within its current 50,000 ft2 (approx. 5,000 m2) facility, Yposkesi operates multiple manufacturing suites for bulk drug substances (up to 1,000 L) and fill and finish to support the growing demand for late-phase projects. In 2023, Yposkesi will bring online additional capacity by increasing its global footprint to 100,000 ft2 (approx. 10,000 m2) with a second large-scale facility designed for EMA and FDA compliance. Yposkesi’s investment in innovation ensures that its bioprocessing platforms deliver high-quality gene-modified cell therapies and in vivo gene therapy projects. Yposkesi’s staff of ~200 employees is located on the Genopole Campus in Corbeil-Essonnes (South of Paris), France.

Company Details

Employees
149
Founded
-
Address
20, Rue Henri Desbruères, Évry,île-De-France 91000,france
Phone
+33 760 113 938
Email
pc****@****esi.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Évry, Île-de-France
Looking for a particular Yposkesi, An Sk Pharmteco Company employee's phone or email?

Yposkesi, An Sk Pharmteco Company Questions

News

Yposkesi $65m expansion doubles viral vector footprint - BioProcess International

Yposkesi $65m expansion doubles viral vector footprint BioProcess International

SK pharmteco doubles viral vector production capacity in Europe - The Korea Herald

SK pharmteco doubles viral vector production capacity in Europe The Korea Herald

With $71M investment, French CDMO Yposkesi set to double capacity and become a viral vector force - Fierce Pharma

With $71M investment, French CDMO Yposkesi set to double capacity and become a viral vector force Fierce Pharma

SK pharmteco Doubles Viral Vector Production Capacity in Europe - Contract Pharma

SK pharmteco Doubles Viral Vector Production Capacity in Europe Contract Pharma

Axovant and Yposkesi team up on gene therapies - The Pharma Letter

Axovant and Yposkesi team up on gene therapies The Pharma Letter

SK acquires 70% stake in Yposkesi to jump into cell, gene CMO business - The Korea Economic Daily Global Edition

SK acquires 70% stake in Yposkesi to jump into cell, gene CMO business The Korea Economic Daily Global Edition

Yposkesi launches LentiSure™, LV vector production platform optimized for higher yields - BioProcess International

Yposkesi launches LentiSure™, LV vector production platform optimized for higher yields BioProcess International

[Bio USA] Yposkesi’s 2nd plant to be in full swing in 2025: VP - The Korea Herald

[Bio USA] Yposkesi’s 2nd plant to be in full swing in 2025: VP The Korea Herald

Top Yposkesi, An Sk Pharmteco Company Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant